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The evolution of enabling technologies and their associated
perspectives into molecular mechanisms underlying disease has extended
beyond the abilities of scientific and clinical structures to advance their
translation into new algorithms that improve the health of patients and
populations.1 Research programs have yielded a vast array of novel
molecules related to pathophysiological mechanisms that represent
diagnostic and therapeutic targets which have the potential for
personalized

healthcare

management.

Yet,

despite

extraordinary

scientific advances, routine successful translation of discovery into new
therapeutic tools remains a distant vision. Beyond constraints in bridging
discovery science with clinical translation due to obstacles in facilities,
resources and in skilled specialized investigators, 95% of therapies brought
into product development by the pharmaceutical and biotechnology
sector eventually fail, reflecting negative balance between efficacy and
adverse effects.
Appreciating the importance of establishing equilibrium between
translation and discovery science, Congress recently enacted the Cures
Acceleration Network (CAN), legislation that will create formal bridges
between

molecular

discoveries

and

new

healthcare

paradigms.

Embracing this mandate to facilitate translation encompassed by CAN,
the leadership of the NIH has created a vigorous path forward by
constituting a new National Center for Advancing Translational Sciences
(NCATS). The portfolio for this Center includes advancing novel laboratorybased discoveries into potential healthcare technologies with reduced
commercial risk, in order to enhance their attractiveness for future
development by the private sector.2 This mandate will be accomplished
by amalgamating programs existing across NIH that can advance the

development of scientific discoveries to cross the translational divide.
These resources include the Molecular Libraries Program (MLP) which
offers high throughput screening capabilities and libraries of compounds
useful for research and as therapeutics. For example, the Chemical
Genomics Center, part of MLP, provides a robotic, high throughput
screening system and a library of >350,000 small molecules to interrogate
fundamental cellular mechanisms. The Therapeutics for Rare and
Neglected Diseases program provides resources for preclinical drug
development centered on rare disorders with limited commercial interest.
Finally, Clinical and Translational Science Awards offer a nationwide
platform of institutions with infrastructures of similar nature and a workforce
that ostensibly, could advance the development of therapeutics through
patient and community-based studies. Coalescing these resources has
tremendous potential to foster interactions between public and private
sectors that optimize the utility of technology cores, minimize risk to lower
barriers

to

commercialization,

and

coordinate

transitions

across

communities of practice (e.g., academic-government, governmentpharmaceutical company) that maximize translational efficiencies.
The genesis of NCATS reflects a modern view of the scientific
continuum from molecules to global populations. It envisions the advance
of translation from a discipline focused on new therapies that palliate
disease, to the quantification of pathobiological risk and disease
prevention.3 This Center will exploit existing and developing capabilities to
optimize the evolution of better patient-centered healthcare algorithms.
Further,

NCATS

will

catalyze

collaborations

between

emanating from siloed communities within and between

stakeholders
discovery,

development, and practice, investing them in a public-private partnership

that is science-based, driving clinical development that enhances
efficiencies and reduces risks associated with the development of the
next generation of healthcare solutions.
Importantly, NCATS will contribute to producing the next generation
of clinical and translational investigators. Equilibrating the balance
between discovery and translation requires a cohort of multidisciplinary
investigators with fluency in the lexicon and paradigms characterizing the
laboratory and clinic, to enable integration of these broadly different
domains.4 Also, re-balancing entails a transition in professional culture that
rewards team science.5 This envisioned future will require the creation of a
brand for clinical and translational science that attracts novice
investigators into training programs, to produce the interdisciplinary teams
which not only maintain the balance between basic and applied science
but most appropriately, are capable of translating a discovery into
therapeutic interventions with great promise for good.4, 6, 7
The creators of NCATS identified clinical pharmacology as one
foundational element essential to success along the discovery-application
continuum.8 This recognition highlights clinical pharmacology as one
discipline at the center of the field of clinical and translational science.
The key role for clinical pharmacology in this emerging science reflects its
historic position as the index discipline bridging the laboratory and
bedside (ie., the translators of translational science). Emanating from the
most fundamental inquiries into drug actions, clinical pharmacology
focuses on two elementary questions: What do drugs do to the body?
and What does the body do to drugs? This concentration on drug action
and disposition yielded the earliest paradigms of individualized medicine
in which the right drug is used in the right patient at the right dose.1,

9

Further, advances in the technologies and approaches emanating from
the

field

of

pharmacometrics

have

further

positioned

clinical

pharmacologists as domain experts at each node of the continuum of
drug discovery, development, regulation, and utilization. The continued
centrality of clinical pharmacology in translational science is evidenced
by its leadership in key international programs linking the laboratory and
clinic, including the Pharmacogenomics Research Network10, the Food
and Drug Administration’s Critical Path Initiative11, and the Institute of
Medicine’s Committee on Qualification of Biomarkers and Surrogate
Endpoints in Chronic Disease12.
While NCATS offers a unique opportunity to energize and further
develop the firmly established discipline of Clinical Pharmacology in the
U.S. and many other parts of the world, it is important that these efforts not
be used as either a tangential or overt attempt to “re-brand” clinical
pharmacology as the emerging field of clinical and translational
science.4,

6, 7

Although translation will be closely served by clinical

pharmacology, especially across the continuum of drug discovery,
development, regulation, and utilization, these disciplines are intersecting
as opposed to their being merely co-existent. The core competencies of
clinical pharmacology, including pharmacogenomics, pharmacokinetics,
pharmacodynamics, pharmacoepidemiology, pharmacovigilence, and
pharmacometrics, to name a few, are tools critical to the therapeutic
translational paradigm. However, they also are essential beyond the
context of clinical and translational science and they will be applied by
investigators who self-identify as clinical pharmacologists, but not
translational investigators. Conversely, core elements of clinical and
translational science go beyond the facets of clinical pharmacology and

thus, the portfolio of abilities of translational scientists who are not trained
in clinical pharmacology, while valuable to the overall effort/goals of
translational science, may not be complete as applied to addressing the
intricacies and idiosyncracies of the drug therapy paradigm. The inherent
risk in re-branding and folding clinical pharmacology into clinical and
translational science is the possibility of dilution, attrition or loss of those
central concepts, approaches and techniques that uniquely identify
clinical pharmacologists as practitioners. The striking contraction of
experienced investigators in the field of whole animal physiology and
pharmacology,

which

were

over-shadowed

by

molecular

experimentalists, serves as a warning to resist enveloping clinical
pharmacology as a discipline, into clinical and translational science, least
we lose the key elements of the former, as a neglected step-child to the
higher profile elements in clinical and translational science.
The new National Center for Advancing Translational Sciences
represents one essential step in advancing the science of translation. It
consolidates national resources and programs whose integration will
maximize the discovery-translation continuum. It will crystallize partnerships
among academic, industry, and government organizations that will
accelerate the evolution of new insights in molecular pathobiology into
novel diagnostics and therapeutic tools in the armamentarium available
for patient care. Further, it will create a professional development path in
clinical and translational science and medicine that will prepare the
cadre of specialized investigators invested in the culture of team science.
This great promise and potential can only be realized in the context of
solving the great challenges that work to minimize the impact of
translation on the healthcare of populations: inclusion of broad

communities of practice, failure rates in drug development, metrics of
performance, and covering the translational medicine continuum. The
goal for the new Center is to gain early adoption of the integration of
discovery science into validated transformational patient-centered
algorithms to address unmet needs in healthcare. The critical path to
realizing this goal leverages the core competencies encompassing
clinical pharmacology as one essential and critical discipline forming the
foundation for the emerging field of clinical and translational science. The
clinical pharmacology community embraces this goal and looks forward
to closely collaborating with NCATS, its leaders, and the diverse
communities of practice contributing to the discovery-application
paradigm to translate this vision into a reality that improves the lives of our
patients.
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